The surface of nanoparticles changes immediately after intravenous injection because blood proteins adsorb on the surface. How this interface changes during circulation and its impact on nanoparticle distribution within the body is not understood. Here, we developed a workflow to show that the evolution of proteins on nanoparticle surfaces predicts the biological fate of nanoparticles in vivo. This workflow involves extracting nanoparticles at multiple time points from circulation, isolating the proteins off the surface and performing proteomic mass spectrometry. The mass spectrometry protein library served as inputs, while blood clearance and organ accumulation were used as outputs to train a supervised deep neural network that predicts nanoparticle biological fate. In a double-blinded study, we tested the network by predicting nanoparticle spleen and liver accumulation with upward of 94% accuracy. Our neural network discovered that the mechanism of liver and spleen uptake is due to patterns of a multitude of nanoparticle surface adsorbed proteins. There are too many combinations to change these proteins manually using chemical or biological inhibitors to alter clearance. Therefore, we developed a technique that uses the host to act as a bioreactor to prepare nanoparticles with predictable clearance patterns that reduce liver and spleen uptake by 50% and 70%, respectively. These techniques provide opportunities to both predict nanoparticle behavior and also to engineer surface chemistries that are specifically designed by the body.

Targeting ligands are conjugated onto nanoparticles to increase their selectivity for diseased cells. However, they become covered by serum proteins which prevent them from binding to target receptors. Here, we show that the nanoparticle protein corona achieved a maximum thickness in serum because the protein adsorption and desorption rates reached an equilibrium. Simulation experiments suggest that the number of molecular interactions between proteins decrease with distance from the nanoparticle surface until the forces are too weak to hold the proteins together. This results in an equilibration state between the proteins on the nanoparticle surface and in biological fluids. Conjugating targeting ligands to this equilibrated protein corona allowed the nanoparticles to bind to target cells in the presence of serum proteins. In contrast, conjugating targeting ligands directly to the nanoparticle surface resulted in a 55% reduction in binding to target cells in serum. We demonstrated this concept using two nanoparticle material types with different surface chemistries. We present a ligand-on-corona conjugation strategy that overcomes the negative impact of serum protein adsorption on nanoparticle cellular targeting.

No abstract

A nanoparticle can hold multiple types of therapeutic and imaging agents for disease treatment and diagnosis. However, controlling the storage of molecules in nanoparticles is challenging, because nonspecific intermolecular interactions are used for encapsulation. Here, we used specific DNA interactions to store molecules in nanoparticles. We made nanoparticles containing DNA anchors to capture DNA-conjugated small molecules. By changing the sequences and stoichiometry of DNA anchors, we can control the amount and ratio of molecules with different chemical properties in the nanoparticles. We modified the cytotoxicity of our nanoparticles to cancer cells by changing the ratio of encapsulated drugs (mertansine and doxorubicin). Specifically controlling the storage of multiple types of molecules allows us to optimize the properties of combination drug and imaging nanoparticles.